Paper Details

  1. Home
  2. Paper Details

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

Author: , ColomboN, DelaloyeJ-F, FlorianiI, JaysonG, KristensenG B, LamontA, LedermannJ A, ParmarM K B, QianW, SwartA M, TorriV, TropéC, WheelerS, du BoisA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Paclitaxel plus platinum chemotherapy improves survival and progression-free survival compared to conventional platinum-based chemotherapy in patients with relapsed platinum-sensitive ovarian cancer.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Despite improvements in the treatment of ovarian cancer, most patients develop recurrent disease within 3 years of diagnosis. There is no agreed second-line treatment at relapse. We assessed paclitaxel plus platinum chemotherapy as such treatment. METHODS: In parallel international, mul...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/s0140-6736(03)13718-x

データ提供：米国国立医学図書館（NLM）

Paclitaxel Plus Platinum: A Promising Combination for Relapsed Ovarian Cancer

Ovarian cancer is a serious disease that often recurs despite initial treatment. This clinical trial investigates the effectiveness of adding paclitaxel to platinum-based chemotherapy as a second-line treatment for patients with platinum-sensitive ovarian cancer that has relapsed. The researchers conducted a large, randomized, international study involving 802 patients. The findings revealed that paclitaxel plus platinum chemotherapy significantly improved both overall survival and progression-free survival compared to conventional platinum-based chemotherapy alone.

Paclitaxel and Platinum: Synergistic Effect Against Relapsed Ovarian Cancer

The study demonstrated a statistically significant difference in overall survival (hazard ratio 0.82, p=0.02) favoring the paclitaxel plus platinum group. This translates to a 7% improvement in 2-year survival compared to the conventional chemotherapy group. Similarly, progression-free survival was significantly better in the paclitaxel plus platinum group (hazard ratio 0.76, p=0.0004), with a 10% improvement in 1-year progression-free survival.

Hope on the Horizon for Ovarian Cancer Patients

This study offers a glimmer of hope for patients with relapsed platinum-sensitive ovarian cancer. The combination of paclitaxel and platinum chemotherapy appears to provide a significant improvement in survival and progression-free survival, potentially extending life and improving quality of life for patients facing this challenging disease. Much like a camel's endurance in the desert, this combination therapy may help patients persevere in their fight against cancer.

Dr.Camel's Conclusion

This research provides compelling evidence that adding paclitaxel to platinum-based chemotherapy offers a significant benefit for patients with relapsed platinum-sensitive ovarian cancer. The study results suggest that this combination therapy may improve survival and delay disease progression. The findings are encouraging and highlight the importance of continued research to develop effective treatments for this difficult disease.

Date :
  1. Date Completed 2003-07-17
  2. Date Revised 2022-03-17
Further Info :

Pubmed ID

12826431

DOI: Digital Object Identifier

10.1016/s0140-6736(03)13718-x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.